An approach to immunotherapy using antibody to IgE in mast cell leukemia.
Passive immunotherapy was attempted in a patient with mast cell leukemia using antibody against IgE. The results of both in vitro and in vivo studies indicate that although receptor sites for IgE were retained by the malignant mast cell, a secretory defect was present characterized by the spontaneous release of histamine and an impaired secretory response to anti-IgE antibody. Anti-IgE antibody selectively and reproducibly reduced the number of circulating mast cells probably by facilitating their permanent uptake by the reticuloendothelial system. Tolerance was not achieved with high dose deaggregated sheep IgG, nor were we able to confirm the effectivity of immunochemotherapy based on linking chlorambucil to antibody directed against the tumor-associated "antigen" IgE.
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000008:administration & dosage; D001666:Binding Sites, Antibody; D002699:Chlorambucil / Q000627:therapeutic use; D006801:Humans; D007106:Immune Sera / Q000032:analysis; D007073:Immunoglobulin E; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000302:isolation & purification; D007167:Immunotherapy; D007938:Leukemia / Q000628:therapy*; D008297:Male; D008407:Mast Cells / Q000276:immunology / Q000378:metabolism; D008875:Middle Aged; D012756:Sheep / Q000276:immunology
D000888:Antibodies, Anti-Idiotypic; D007106:Immune Sera; D007074:Immunoglobulin G; D002699:Chlorambucil; D007073:Immunoglobulin E